BlueOcean Ventures
VC Fund
Plan-les-ouates, Switzerland
BlueOcean Ventures is a VC fund in Plan-les-ouates focused on Health Care and Medical. BlueOcean Ventures SA provides capital, operational and company development advisory support (mentoring, company management, divestment experience, network, negotiation support) to entrepreneurs in Switzerland. BlueOcean Ventures is based in Geneva, Switzerland.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries BlueOcean Ventures invests in
Health CareMedicalPersonal HealthBiotechnologyMedical Device
Stages BlueOcean Ventures invests in
SeedSeries ASeries BFunding RoundVenture - Series Unknown
Countries BlueOcean Ventures invests in
SwitzerlandIndiaFranceBulgariaSingapore
Round sizes
Seed $1M–$3.1MSeries A $2.3M–$20M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Seed
- $1M–$3.1M
- Series A
- $2.3M–$20M
Investment Focus
Industry
- Health Care 11 (65%)
- Medical 8 (47%)
- Personal Health 7 (41%)
- Biotechnology 5 (29%)
- Medical Device 5 (29%)
Stage
- Seed 5 (29%)
- Series A 5 (29%)
- Series B 3 (18%)
- Funding Round 3 (18%)
- Venture - Series Unknown 1 (6%)
Country
- Switzerland 11 (65%)
- India 2 (12%)
- France 1 (6%)
- Bulgaria 1 (6%)
- Singapore 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Thomas Zehnder
Partner
|
Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
RockFlow
|
RockFlow is an artificial intelligence fintech company headquartered in Singapore, with offices in 5 countries and regions worldwide. As a next-generation AI-native trading platform, RockFlow offers users a personalized AI investment assistant. It delivers real-time trading insights and position management services tailored to individual targetreturns, risk preferences, and other criteria.The team has a background in cross-border innovation and rich practical and continuous entrepreneurial experience in artificial intelligence, financial engineering, and technology industries. The core members of the company come from top technology companies and financial institutions such as Facebook, Baidu, ByteDance, Huawei, Intel, Vanguard Group, Goldman Sachs, CITIC Securities, and ORC. Many members graduated from top universities in the world, such as MIT, Imperial College London, University of California, Berkeley, and Columbia University.As an AI investment platform, RockFlow is committed to achieving financial equality through AI, allowing everyone to easily experience the joy of simple investment. The product has 9 languages and users are located in more than 30 countries and regions around the world.Since its inception, RockFlow has received $10 million Angel Round Financing led by BlueRun Ventures. Since its inception, RockFlow has been a major promoter of investment innovation, trusted by top global financial institutions and Silicon Valley dollar funds. Current partners include NASDAQ, HKEx, Refinitiv, NYSE, ICE, Interactive Brokers, and HSBC. | Venture - Series Unknown / Nov 20, 2025 | |
UGX.ai
|
UGX.ai is a manufacturing firm with real time traceability and AI based quality inspection for complete operational visibly. | $1M / Seed / Sep 18, 2025 | |
nPloy
|
nPloy is the job platform that transforms the way employers and candidates find the perfect match.We know that job hunting can be an unnecessarily complicated and mundane process. On the other side, talent search has become excessively expensive and consuming in terms of time and energy. nPloy stands against all of this.employ's mission isto provide candidates with the job hunting experience that works and to save organizations from the hassle linked to a talent search. Candidates prefer nPloy for its easy-to-use interface and unique features, such as 100% anonymity, and guaranteed feedback from employers. Companies trust nPloy for its diverse talent pool, and modern approach towards exploring and reaching talents.With more than 160 partners & 35,000 users (and growing), we keep improving your talent and job searching experience. | $2.2M / Seed / Nov 23, 2023 | |
Mikajaki
|
Mikajaki is an innovative automated multi-patient ocular diagnostics platform. The platform enables the use of digital technology, robots, AI, and data, allowing patients and eye specialists access to the specific treatment they require. Mikajaki is currently collaborating with ophthalmology clinic groups across the world to test and implementEyeLib. | $2.5M / Seed / Jun 08, 2020 | |
CyanoGuard AG
|
Cyanoguard AG is a chemical technology company specialised in the development of novel toxin detection methods to improve environmental monitoring, food safety and health care in remote settings and locations. Its innovative technology enables fast and safe cyanide detection in food, waste water and other samples. Its method is selective andrequires no special training and/or equipment.Equipped with the latest research, and with over six years of close collaboration with leading industry partners, the company is dedicated to resolve today's cyanide issues, offering fast and safe toxin detection in any setting at any time. | $3.1M / Seed / Apr 14, 2020 | |
99RetailStreet
|
99RetailStreet is a common commerce platform on cloud targeted at the large unorganized retail segment comprising of “Kiranas/ Kades”, Pharmacies and other consumer facing retail businesses in developing markets. It is built to enhance the retailers’ business through faster Sales Growth, better Financial Capabilities and improved Efficiencyacross the value chain. | Seed / Jun 09, 2017 | |
Ava
|
Ava makes it easy to gain a profound and accurate understanding of your cycle and health—empowering you to make informed choices for your life. Because we believe every woman deserves greater control over her wellbeing, and the tools to maximize her physical and emotional potential. | $9.7M / Series A / Nov 15, 2016 | |
Distalmotion
|
Distalmotion is a medical device company founded and based in Lausanne, Switzerland. Our mission is to remove the complexity out of robotic surgery in order to establish a new standard of care, where all patients in general surgery, gynecology and urology have access to best-in-class minimally invasive care. To do so, we have developed a surgicalrobot called Dexter. Designed, developed and manufactured in Switzerland, Dexter integrates the benefits of laparoscopy and robotics. Dexter combines the affordability of laparoscopy with the benefits of robotics through his novel, on-demand approach to robotic surgery. For further information, visit: dexter.surgery and follow us on LinkedIn and Twitter: @Distalmotion. | Series A / Aug 21, 2013 | |
Abionic
|
Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abionic uses these highly advanced technologies to provide the medical profession with a novel diagnostic tool designed to give patients personal allergyprofiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection.Abionic SA is a certified ISO 9001/13485 company, including research, development and commercialization of in vitro diagnostic devices for allergies detection. The standard ISO 13485 specifies requirements for a quality management system where an organization has to demonstrate its ability to provide medical devices and related services that consistently meet customer and regulatory requirements.Abionic SA is a privately owned high-tech company and is strongly supported by the Swiss Federal Institute of Technology of Lausanne (EPFL), The Canton of Vaud and Venturelab.Abionic was founded by former scientists from the biomedical optics laboratory (LOB) at EPFL. Its headquarters are located in Lausanne, Switzerland.Abionic appreciates the support it has received from: | $2.3M / Series A / Apr 26, 2012 | |
Myopowers Medical Technologies
|
Myopowers Medical Technologies is a French medical device company that develops innovative technologies to provide muscle assistance to patients with high unmet medical needs. The technology can be applied to a number of indications in the GI, cardiology or urology area.The company focus is the development of ARTUS, a new and unique implantabledevice for the treatment of stress urinary incontinence. Stress urinary incontinence is a condition that affects millions of people around the world. Unfortunately, currently available products are old with significant limitations such as tissue erosion, infection or mechanical failure leading frequent re-operation.ARTUS is made of smooth and flat silicon cuff placed around the urethra. It is individually actionable and adjustable with a remote control allowing patients easy voiding and the surgeon monitoring and adjusting the cuff. This device is the first artificial urinary system specifically designed to include the treatment of female patients who account for a vast majority of the urinary incontinence market. | $16M / Series B / Jul 05, 2011 | |
| See all 17 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Medical Device Investors
11,047 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
FAQ
What does BlueOcean Ventures invest in?
BlueOcean Ventures invests primarily in Health Care, Medical and Personal Health startups, most often at Seed and Series A stage. Most of the 17 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is BlueOcean Ventures's check size?
BlueOcean Ventures typically joins rounds of $1M–$3.1M at Seed and $2.3M–$20M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds BlueOcean Ventures participates in.
How do I contact BlueOcean Ventures?
Public channels for BlueOcean Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at BlueOcean Ventures?
The team at BlueOcean Ventures includes Thomas Zehnder (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
